No Data
No Data
Qyuns Therapeutics Invests 260 Million Yuan in Financial Products
Qyuns Therapeutics (HKG:2509) spent an aggregate of 260 million yuan on wealth management products offered by three banks. The subscriptions were made between April 12 and June 4 to maximize the use o
Express News | Qyuns Therapeutics- on May 29. Agreed to Subscribe for Wealth Management Products Offered by Shanghai Pudong Development Bank of RMB100 Mln
Express News | Qyuns Therapeutics - on April 18 Agreed to Subscribe for Wealth Management Products Offered by Bank of Jiangsu With Subscription Amount of RMB50 Mln
Express News | Qyuns Therapeutics- on June 4, Co Entered Subscription Agreement With Icbc to Subscribe for Wealth Management Products for RMB50 Mln
Hong Kong stocks in flux | Quansheng Biological-B (02509) rose more than 10% in the afternoon. The research results of the treatment of PN injection fluid showed that the main endpoint was reached.
In the afternoon, Quanxin Biopharmaceuticals B (02509) rose more than 10% on high volume. As of press time, it increased by 4.25% to HK$24.55, with a turnover of HK$2.1389 million.
Qyuns Therapeutics Releases Data From Phase 2 Trial for Prurigo Nodularis Drug
Qyuns Therapeutics (HKG:2509) released data from its phase 2 trial for its drug for prurigo nodularis during a meeting of the Chinese Society of Dermatology, according to a Friday filing with the Hong
No Data